Cherenkov imaging uses special BeamSite cameras to capture radiation beam interaction with tissue, making radiation oncology treatments a visual process.
Radiation oncologists can now see their treatment delivery in action. A new method that captures imaging and real-time video of the beam directly on the patient allows providers to see exactly what they are doing – and to make changes when necessary.
Known as Cherenkov imaging, this technique, developed by the Dartmouth-Hitchcock Norris Cancer Center (NCCC) and Dartmouth spin-off company DoseOptics, LLC, turns radiation therapy into a visual process, says the company’s co-founder.
“Cherenkov imaging provides visualization of the radiation therapy treatment, so that the treatment team can see everything and make adjustments when unexpected things happen,” said Brian Pogue, Ph.D., DoseOptics, LLC, co-founder and co-director of the NCCC Translational Engineering in Cancer Research Program.
When photon or electron radiation beams hit tissue, such as skin, it produces a small light emission from the surface, known as the Cherenkov effect. BeamSite cameras, also developed by DoseOptics, LLC, can capture real-time images of the treatment-beam shape, as well as show intensity levels that are proportional to the radiation dose. That data can be used to verify the accuracy of dose and beam delivery for each daily treatment, he said. Standard quality assurance measure cannot do this, he said.
The NCCC is the first cancer center in the world to install BeamSite Cherenkov imaging cameras into radiotherapy treatment rooms. Based on their initial experiences with the system, a team from Dartmouth published findings recently in The International Journal of Radiation Oncology, Biology, Physics.
To gather their data, the team, led by lead study author Lesley Jarvis, M.D., Ph.D., associate professor of medicine at Dartmouth’s Geisel School of Medicine and member of NCCC’s Translational Engineering in Cancer Research program, followed 64 patients receiving treatment for breast cancer, sarcoma, lymphoma, or other cancers.
Based on their analysis, six patients would have benefited from adjustments. For breast treatments, the Cherenkov images pinpointed instances where treatment delivery introduced dose to the contralateral breast, the arm, or the chin, as well as non-ideal bolus positioning. In addition, investigators found, with sarcoma patients, that there was no unintended exposure to the opposite leg, confirming that inadvertent dose was not a problem.
Although national statistics indicate a roughly 1-percent incidence rate of incorrect radiation therapy delivery, Pogue said, Cherenkov imaging still offers value for patient care.
“Normally, treatments are just fine,” he said. “However, if you cannot see where the beam is, then it is a blind treatment, and the interaction between patients and therapy team is just less natural than it could be if the treatment was visual.”
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.